Released May 7, 2026, after the close
10-Q filed May 7, 2026, 37 days after period end · 0001104659-26-057198
Q1 2026 · 10-Q
Revenue$5.34M$5.34M +128.0% vs Q1 2025−20.5% vs Q4 2025
Net Income-$7.05M-$7.05M N/M vs Q1 2025N/M vs Q4 2025
EPS Diluted$0.19$0.19 −47.2% vs Q1 2025no prior Q4 2025 on file
Gross Profit$3,832,000+106.8%
Operating Income-$8,021,000N/M
Operating Cash Flow-$8,583,000N/M
Margins · derived
Gross margin71.8%−7.4 pt vs Q1 2025
Operating margin-150.3%+326.7 pt vs Q1 2025
Net margin-132.2%+325.9 pt vs Q1 2025
What the release said
The release
Same quarter
| Metric | Q1 2026 | Q1 2025 | Q1 2024 |
|---|---|---|---|
| Revenue | $5.34M | $2.34M | $1.22M |
| Net Income | -$7.05M | -$10.72M | -$6.59M |
| EPS Diluted | $0.19 | $0.36 | $0.27 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Profound Medical Corp. · CIK 1628808 · Engraved from SEC EDGAR